RESUMEN
BACKGROUND: In Lesch-Nyhan disease (LND), early dopamine deficiency is thought to contribute to dystonia and self-injury, gradually developing over the first years of life. Previous attempts to restore dopamine levels in older patients have been unsuccessful. Based on the hypothesis that very early dopamine replacement can prevent full phenotypic development, we treated three patients with LND from infancy with levodopa. METHODS: Levodopa/carbidopa (4:1) was started at age 11 to 13 months, aiming at escalating to 5 to 6 mg/kg levodopa per day. Follow-up focused on dystonia severity and whether self-injury occurred. In addition, the literature was reviewed to delineate the age at onset of self-injury for all reported cases to date. RESULTS: During long-term follow-up, self-injury appears to have been prevented in two patients (now aged 14 and 15.5 years), as their HPRT1 gene mutations had been invariably associated with self-injury before. Future self-injury is unlikely, as only 1.1% of 264 published cases had self-injury onset later in life than these patients' current ages. The third patient started self-injury at age 1.5 years, while on a substantially lower levodopa dose. A clear effect of levodopa on dystonia could not be determined. CONCLUSIONS: Our observations suggest that levodopa, given early enough and sufficiently dosed, might be able to prevent self-injury in LND. Therefore, levodopa could be considered in patients with LND as early as possible, at least before the self-injury appears. Further research is needed to establish very early levodopa as an effective treatment strategy in LND, and to optimize timing and dosing.
Asunto(s)
Síndrome de Lesch-Nyhan , Levodopa , Conducta Autodestructiva , Humanos , Levodopa/administración & dosificación , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Conducta Autodestructiva/tratamiento farmacológico , Conducta Autodestructiva/prevención & control , Conducta Autodestructiva/etiología , Adolescente , Masculino , Femenino , Lactante , Carbidopa/administración & dosificación , Carbidopa/farmacología , Dopaminérgicos/administración & dosificación , Dopaminérgicos/farmacología , Combinación de MedicamentosRESUMEN
This study explored the effect of naringin (NAR) on HGPRT1 deficiency and hyperuricemia through NOS-cAMP-PKA and BDNF/TrkB signaling pathways induced by caffeine (CAF) and KBrO3 in a rat model. Sixty-three adult male albino rats were randomly assigned into nine (n = 7) groups. Group I: control animals, Group II was treated with 100 mg/kg KBrO3 , Group III was treated with 250 mg/kg CAF, Group IV was treated with 100 mg/kg KBrO3 + 250 mg/kg CAF, Group V was administered with 100 mg/kg KBrO3 + 100 mg/kg haloperidol, Group VI was administered with 100 mg/kg KBrO3 + 50 mg/kg NAR, Group VII was administered with 500 mg/kg CAF + 50 mg/kg NAR, and Group VIII was administered with 100 mg/kg KBrO3 + 250 mg/kg CAF + 50 mg/kg NAR. Finally, group IX was treated with 50 mg/kg NAR. The exposure of rats to KBrO3 and CAF for 21 days induced renal dysfunction linked with Lesch-Nyhan disease. NAR obliterated renal dysfunction linked with Lesch-Nyhan disease by decreasing uric acid, renal malondialdehyde level, inhibiting the activities of arginase, and phosphodiesterase-51 (PDE-51) with corresponding upregulation of brain derived-neurotrophic factor and its receptor (BDNF-TrkB), Bcl11b, HGPRT1, and DARPP-32. Additionally, renal failure related to Lesch-Nyhan disease was remarkably corrected by NAR as shown by the reduced activities of AChE and enzymes of ATP hydrolysis (ATPase, AMPase, and ADA) with affiliated increase in the NO level. This study therefore validates NAR as nontoxic and effective chemotherapy against kidney-related Lesch-Nyhan disease by mitigating effects of toxic food additives and enzymes of ATP-hydrolysis via NOS-cAMP-PKA and BDNF/TrkB signaling pathways.
Asunto(s)
Flavanonas , Síndrome de Lesch-Nyhan , Insuficiencia Renal , Masculino , Ratas , Animales , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Síndrome de Lesch-Nyhan/metabolismo , Factor Neurotrófico Derivado del Encéfalo , Cafeína , Adenosina TrifosfatoRESUMEN
BACKGROUND: Lesch-Nyhan disease (LND) is a disease of purine metabolism linked to chromosome X due to the absence or near-absence of enzyme hypoxanthine-guanine phosphoribosyltransferase. Patients with LND have a compulsive autoaggressive behavior that consists of self-mutilation by biting. METHODS: The objective of this study was to explore the safety and efficacy of botulinum toxin (BoNT) injected into the masticatory muscles and biceps brachii to reduce self-mutilation in patients with LND. We retrospectively analyzed six patients with LND who were treated with BoNT to prevent automutilatory behavior. RESULTS: The patient ages when started on treatment with BoNT were 4, 4.5, 6.6, 7.9, 13.9, and 32.3 years. Patients received a mean number of injections of 20, ranging from 3 to 29, over a period that ranged from 1.5 to 7.1 years. The maximum total dose of Botox was 21.3 units/kg mean and the maximum total dose of Dysport was 37.5 units/kg mean. A total of 119 injections were performed. Of these 113 (95%) were partially or completely effective. Only three of 119 injections (2.5%) produced adverse effects. CONCLUSIONS: Botulinum toxin is useful and safe for the treatment of self-biting behavior in patients with LND.
Asunto(s)
Toxinas Botulínicas/farmacología , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Músculos Masticadores/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Fármacos Neuromusculares/farmacología , Automutilación/tratamiento farmacológico , Adolescente , Brazo , Toxinas Botulínicas/administración & dosificación , Toxinas Botulínicas/efectos adversos , Niño , Femenino , Humanos , Masculino , Fármacos Neuromusculares/administración & dosificación , Fármacos Neuromusculares/efectos adversos , Evaluación de Resultado en la Atención de SaludRESUMEN
Lesch-Nyhan disease (LND) is a rare monogenic disease caused by deficiency of the salvage pathway enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). LND is characterized by severe neuropsychiatric symptoms that currently cannot be treated. Predictive in vivo models are lacking for screening and evaluating candidate drugs because LND-associated neurological symptoms are not recapitulated in HGPRT-deficient animals. Here, we used human neural stem cells and neurons derived from induced pluripotent stem cells (iPSCs) of children affected with LND to identify neural phenotypes of interest associated with HGPRT deficiency to develop a target-agnostic-based drug screening system. We screened more than 3000 molecules and identified 6 pharmacological compounds, all possessing an adenosine moiety, that corrected HGPRT deficiency-associated neuronal phenotypes by promoting metabolism compensations in an HGPRT-independent manner. This included S-adenosylmethionine, a compound that had already been used as a compassionate approach to ease the neuropsychiatric symptoms in LND. Interestingly, these compounds compensate abnormal metabolism in a manner complementary to the gold standard allopurinol and can be provided to patients with LND via simple food supplementation. This experimental paradigm can be easily adapted to other metabolic disorders affecting normal brain development and functioning in the absence of a relevant animal model.
Asunto(s)
Células Madre Pluripotentes Inducidas/citología , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Síndrome de Lesch-Nyhan/terapia , Células-Madre Neurales/citología , Alopurinol/uso terapéutico , Animales , Estudios de Casos y Controles , Diferenciación Celular , Modelos Animales de Enfermedad , Humanos , Hipoxantina Fosforribosiltransferasa/genética , Células-Madre Neurales/enzimología , FenotipoRESUMEN
Background: Lesch-Nyhan disease (LND) is a rare X-linked recessive inborn error of purine metabolism. Late diagnosis of LND may cause significant morbidity. LND cases have never been reported in Indonesia.Case report: A 15-year-old male who had been diagnosed with cerebral palsy was referred to our hospital due to renal failure requiring emergency dialysis. The patient presented with three classic manifestations of LND: increased uric acid levels, neurological disorders, and self-injurious behaviors. LND was suspected because of an abscess-like lump on the left ankle that was confirmed to be a tophus, which had burst and discharged thick masses containing blood, debris, and white crystal materials. The diagnosis of LND was confirmed by the presence of a deletion to exon 1 of the HPRT1 gene. The patient received oral allopurinol daily and treatment for end-stage renal disease (ESRD), which included regular dialysis and subcutaneous administration of erythropoietin. At a 2-month follow-up, he improved clinically with a 71% decrease in uric acid levels after regular dialysis and allopurinol treatment.Conclusion: In developed countries, LND can be diagnosed as early as 3 days after birth. However, diagnosis in the present case was delayed due to the rarity of the disease and the limited number of facilities in Indonesia that offer genetic counseling. Late diagnosis of LND leads to ESRD and irreversible abnormalities. This is the first case of LND presenting with a unique clinical presentation of tophus burst reported in Indonesia.
Asunto(s)
Parálisis Cerebral/complicaciones , Fallo Renal Crónico/etiología , Síndrome de Lesch-Nyhan/complicaciones , Síndrome de Lesch-Nyhan/diagnóstico , Adolescente , Alopurinol/uso terapéutico , Diagnóstico Tardío , Exones , Supresores de la Gota/uso terapéutico , Humanos , Hipoxantina Fosforribosiltransferasa/genética , Fallo Renal Crónico/terapia , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Síndrome de Lesch-Nyhan/genética , Masculino , Radiografía Torácica , Diálisis Renal , Escoliosis/etiología , Ácido Úrico/sangreRESUMEN
Lesch-Nyhan disease (LND) is a rare X-linked genetic disorder, with complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, uric acid (UA), hypoxanthine and xanthine accumulation, and a devastating neurologic syndrome. UA excess, causing renal failure, is commonly decreased by xanthine oxidoreductase (XOR) inhibitors, such as allopurinol, yielding a xanthine and hypoxanthine increase. Xanthine accumulation may result in renal stones, while hypoxanthine excess seems involved in the neurological disorder. Inhibition of purine nucleoside phosphorylase (PNP) represents a different strategy for lowering urate. PNP catalyzes the cleavage of purine ribo- and d-ribo-nucleosides into ribose/deoxyribose phosphate and free bases, starting catabolism to uric acid. Clinical trials demonstrated that PNP inhibitors, initially developed as anticancer drugs, lowered UA in some gouty patients, in association or not with allopurinol. The present study tested the reliability of an analogue of immucillin-G (C1a), a PNP inhibitor, as a therapy for urate, hypoxanthine, and xanthine excess in LND patients by blocking hypoxanthine production upstream. The therapeutic aim is to limit the administration of XOR inhibitors to LND patients by supplying the PNP inhibitor in low doses, avoiding d-nucleoside toxicity. We report studies conducted in primary cultures of skin fibroblasts from controls and LND patients grown in the presence of the PNP inhibitor. Cell viability, oxypurine release in culture medium, and endocellular nucleotide pattern have been monitored in different growth conditions (inhibitor concentration, time, added inosine). Our results demonstrate effective PNP inhibition by low inhibitor concentration, with reduced hypoxanthine release, and no appreciable toxicity in control or patient cells, suggesting a new therapeutic strategy for LND hyperuricemia.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Hiperuricemia/tratamiento farmacológico , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Purina-Nucleósido Fosforilasa/antagonistas & inhibidores , Pirimidinonas/farmacología , Pirroles/farmacología , Alopurinol/farmacología , Células Cultivadas , Humanos , Hiperuricemia/metabolismo , Hipoxantina/farmacología , Hipoxantina Fosforribosiltransferasa/metabolismo , Síndrome de Lesch-Nyhan/metabolismo , Purinas/metabolismo , Reproducibilidad de los Resultados , Ácido Úrico/metabolismo , Xantina/farmacologíaAsunto(s)
Alopurinol/uso terapéutico , Cálculos Renales/tratamiento farmacológico , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Preescolar , Humanos , Riñón/diagnóstico por imagen , Cálculos Renales/diagnóstico por imagen , Cálculos Renales/etiología , Síndrome de Lesch-Nyhan/complicaciones , Masculino , Recurrencia , Insuficiencia del Tratamiento , UltrasonografíaAsunto(s)
Fluidoterapia , Hipoxantina Fosforribosiltransferasa/deficiencia , Cálculos Renales/terapia , Síndrome de Lesch-Nyhan/complicaciones , Xantina/metabolismo , Alopurinol/efectos adversos , Preescolar , Humanos , Concentración de Iones de Hidrógeno , Hipoxantina Fosforribosiltransferasa/genética , Riñón/diagnóstico por imagen , Riñón/metabolismo , Cálculos Renales/diagnóstico por imagen , Cálculos Renales/etiología , Cálculos Renales/metabolismo , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Síndrome de Lesch-Nyhan/metabolismo , Síndrome de Lesch-Nyhan/orina , Masculino , Mutación , Citrato de Potasio/administración & dosificación , Recurrencia , Eliminación Renal , Ultrasonografía , Orina/química , Xantina/química , Xantina/orina , Xantina Oxidasa/antagonistas & inhibidores , Xantina Oxidasa/metabolismoRESUMEN
BACKGROUND: Lesch-Nyhan syndrome is a rare inborn error of purine metabolism marked by a complete deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT). Inherited as an X-linked recessive genetic disorder that primarily affects males, patients with Lesch-Nyhan syndrome exhibit severe neurological impairments, including choreoathetosis, ballismus, cognitive dysfunction, and self-injurious behavior. Uric acid levels are usually abnormally high, leading to kidney and bladder stones which often necessitate urological intervention. Factor V Leiden is an autosomal dominant disorder of blood clotting associated with hypercoagulability, thrombophilia, and renal disease. CASE PRESENTATION: We present the first reported case of xanthine calculi in a patient with Lesch-Nyhan syndrome and Factor V Leiden who was treated with allopurinol. A renal ultrasound and CT scan demonstrated bilateral staghorn calculi in the kidneys as well as nephrocalcinosis. Two years earlier the patient underwent cystoscopy with bilateral ureteroscopy and laser lithotripsy, and he was stone free afterwards. The patient subsequently underwent bilateral percutaneous nephrolithotomy (PCNL) and was stone free following the procedure. Patients with endogenous overproduction of uric acid who are being treated with allopurinol have a higher chance of developing xanthine stones. CONCLUSIONS: Pediatricians treating these children should be aware of these rare conditions and promptly manage the potential complications that may require medical or surgical intervention.
Asunto(s)
Alopurinol/efectos adversos , Antimetabolitos/efectos adversos , Factor V/genética , Cálculos Renales/etiología , Síndrome de Lesch-Nyhan/complicaciones , Mutación Puntual , Xantina Oxidasa/antagonistas & inhibidores , Alopurinol/uso terapéutico , Antimetabolitos/uso terapéutico , Niño , Humanos , Cálculos Renales/sangre , Cálculos Renales/química , Cálculos Renales/terapia , Síndrome de Lesch-Nyhan/sangre , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Masculino , Xantina/metabolismoRESUMEN
BACKGROUND: Patients with deficient hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity present hyperuricemia and/or hyperuricosuria, with a variable degree of neurological manifestations. Hyperuricemia in HPRT deficiency is due to uric acid overproduction and is frequently treated with allopurinol. Renal uric acid excretion is sharply increased in these patients. In recent years, several renal tubular urate transporter single nucleotide polymorphisms (SNPs), including those of the GLUT9, ABCG2 and URAT1 genes, have been described that influence the renal handling of uric acid and modulate serum urate levels. In the present study, we analyzed whether GLUT9, ABCG2 and URAT1 gene SNPs are able to influence uric acid levels and allopurinol response in patients with HPRT deficiency. METHODS: Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years. RESULTS: Patients with HPRT deficiency having allele A of rs16890979 in the GLUT9 gene present with a lower serum urate concentration at diagnosis, before allopurinol treatment is instituted, and need lower allopurinol doses to maintain serum urate levels between 268 and 446 µmol/L (4.5 and 7.5 mg/dL). No relationship between rs2231142 in the ABCG2 gene or rs11231825 in the URAT1 gene and serum urate levels or allopurinol response was found in our patients with HPRT deficiency. CONCLUSIONS: GLUT9 SNPs influence the renal handling of uric acid and modulate serum urate levels and the response to treatment in patients with uric acid overproduction due to HPRT deficiency.
Asunto(s)
Proteínas Facilitadoras del Transporte de la Glucosa/genética , Gota/genética , Hiperuricemia/genética , Síndrome de Lesch-Nyhan/genética , Polimorfismo de Nucleótido Simple , Ácido Úrico/sangre , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/genética , Adolescente , Adulto , Alopurinol/uso terapéutico , Biomarcadores/sangre , Niño , Preescolar , Predisposición Genética a la Enfermedad , Proteínas Facilitadoras del Transporte de la Glucosa/metabolismo , Gota/sangre , Gota/diagnóstico , Gota/tratamiento farmacológico , Supresores de la Gota/uso terapéutico , Humanos , Hiperuricemia/sangre , Hiperuricemia/diagnóstico , Hiperuricemia/tratamiento farmacológico , Síndrome de Lesch-Nyhan/sangre , Síndrome de Lesch-Nyhan/diagnóstico , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Persona de Mediana Edad , Proteínas de Neoplasias/genética , Transportadores de Anión Orgánico/genética , Proteínas de Transporte de Catión Orgánico/genética , Fenotipo , Eliminación Renal , Resultado del Tratamiento , Adulto JovenRESUMEN
PURPOSE: Because of the evolutionary loss of the uricolytic pathway, humans accumulate poorly soluble urate as the final product of purine catabolism. Restoration of uricolysis through enzyme therapy is a promising treatment for severe hyperuricemia caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT). To this end, we studied the effect of PEG conjugation on the activity and stability of the enzymatic complement required for conversion of urate into the more soluble (S)-allantoin. METHODS: We produced in recombinant form three zebrafish enzymes required in the uricolytic pathway. We carried out a systematic study of the effect of PEGylation on the function and stability of the three enzymes by varying PEG length, chemistry and degree of conjugation. We assayed in vitro the uricolytic activity of the PEGylated enzymatic triad. RESULTS: We defined conditions that allow PEGylated enzymes to retain native-like enzymatic activity even after lyophilization or prolonged storage. A combination of the three enzymes in an appropriate ratio allowed efficient conversion of urate to (S)-allantoin with no accumulation of intermediate metabolites. CONCLUSIONS: Pharmaceutical restoration of the uricolytic pathway is a viable approach for the treatment of severe hyperuricemia.
Asunto(s)
Amidohidrolasas/química , Carboxiliasas/química , Hipoxantina Fosforribosiltransferasa/deficiencia , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Polietilenglicoles/química , Urato Oxidasa/química , Uricosúricos/química , Alantoína/química , Animales , Terapia Enzimática , Humanos , Hiperuricemia/tratamiento farmacológico , Peso Molecular , Proteínas Recombinantes/química , Solubilidad , Estereoisomerismo , Ácido Úrico/química , Pez CebraRESUMEN
Excess of uric acid is mainly treated with xanthine oxidase (XO) inhibitors, also called uricostatics because they block the conversion of hypoxanthine and xanthine into urate. Normally, accumulation of upstream metabolites is prevented by the hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme. The recycling pathway, however, is impaired in the presence of HPRT deficiency, as observed in Lesch-Nyhan disease. To gain insights into the consequences of purine accumulation with HPRT deficiency, we investigated the effects of the XO inhibitor allopurinol in Hprt-lacking (HPRT-/-) mice. Allopurinol was administered in the drinking water of E12-E14 pregnant mothers at dosages of 150 or 75 µg/ml, and mice sacrificed after weaning. The drug was well tolerated by wild-type animals and heterozygous HPRT+/- mice. Instead, a profound alteration of the renal function was observed in the HPRT-/- model. Increased hypoxanthine and xanthine concentrations were found in the blood. The kidneys showed a yellowish appearance, diffuse interstitial nephritis, with dilated tubules, inflammatory and fibrotic changes of the interstitium. There were numerous xanthine tubular crystals, as determined by HPLC analysis. Oil red O staining demonstrated lipid accumulation in the same location of xanthine deposits. mRNA analysis showed increased expression of adipogenesis-related molecules as well as profibrotic and proinflammatory pathways. Immunostaining showed numerous monocyte-macrophages and overexpression of alpha-smooth muscle actin in the tubulointerstitium. In vitro, addition of xanthine to tubular cells caused diffuse oil red O positivity and modification of the cell phenotype, with loss of epithelial features and appearance of mesenchymal characteristics, similarly to what was observed in vivo. Our results indicate that in the absence of HPRT, blockade of XO by allopurinol causes rapidly developing renal failure due to xanthine deposition within the mouse kidney. Xanthine seems to be directly involved in promoting lipid accumulation and subsequent phenotype changes of tubular cells, with activation of inflammation and fibrosis.
Asunto(s)
Alopurinol/farmacología , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Nefritis/tratamiento farmacológico , Xantina Oxidasa/antagonistas & inhibidores , Xantina/metabolismo , Animales , Hipoxantina Fosforribosiltransferasa/genética , Síndrome de Lesch-Nyhan/genética , Síndrome de Lesch-Nyhan/metabolismo , Síndrome de Lesch-Nyhan/patología , Ratones , Ratones Noqueados , Nefritis/genética , Nefritis/metabolismo , Nefritis/patología , Xantina Oxidasa/genética , Xantina Oxidasa/metabolismoRESUMEN
Lesch-Nyhan disease (LND) is a rare X-chromosomal purine metabolism disorder. LND is characterized by self-injurious behavior (SIB) for which there is no drug treatment. This commentary places a recent clinical study by Khasnavis et al. (Mol. Genetic. Metab., in press) on drug treatment of SIB into a broader context. Although the study by Khasnavis et al. was no break-through in terms of "positive" results, nonetheless, it presents an excellent model of how clinical studies in general and clinical studies on rare diseases should be conducted.
Asunto(s)
Benzazepinas/efectos adversos , Antagonistas de Dopamina/efectos adversos , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Benzazepinas/uso terapéutico , Ensayos Clínicos Fase II como Asunto , Estudios Cruzados , Antagonistas de Dopamina/uso terapéutico , Humanos , Síndrome de Lesch-Nyhan/genética , Síndrome de Lesch-Nyhan/metabolismo , Receptores de Dopamina D2/metabolismo , Tamaño de la Muestra , Insuficiencia del TratamientoRESUMEN
CASE REPORT: We report on a male patient with Tuberous Sclerosis Complex (TSC), which was prenatally diagnosed. At the age of 3 months the patient developed acute renal failure with excessive hyperuricemia. Kidney function improved after rehydration and application of rasburicase, however without full recovery. Due to the inappropriate high levels of uric acid compared to kidney function, screening of hypoxanthine-guanine phosphoribosyltransferase (HPRT) related diseases was initiated. Mutation analysis revealed a deletion of exon 2 and 3 of the HPRT gene confirming the diagnosis of Lesch-Nyhan Disease (LND). After initiation of allopurinol therapy renal function further improved. In the following months the patient developed clinically a typical neurological phenotype of LND and TSC with seizures, severe dystonia and developmental delay. CONCLUSION: Acute renal failure is a rare complication of HPRT related diseases. Combination of two inherited diseases may lead to a delayed diagnosis due to a mixed and maybe misleading phenotype.
Asunto(s)
Lesión Renal Aguda/etiología , Hiperuricemia/etiología , Síndrome de Lesch-Nyhan/complicaciones , Esclerosis Tuberosa/complicaciones , Lesión Renal Aguda/terapia , Alopurinol/uso terapéutico , Discapacidades del Desarrollo/etiología , Distonía/etiología , Exones , Fluidoterapia , Supresores de la Gota/uso terapéutico , Humanos , Hiperuricemia/tratamiento farmacológico , Hipoxantina Fosforribosiltransferasa/genética , Lactante , Síndrome de Lesch-Nyhan/diagnóstico , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Síndrome de Lesch-Nyhan/genética , Masculino , Fenotipo , Convulsiones/etiología , Urato Oxidasa/uso terapéuticoRESUMEN
Lesch-Nyhan disease (LND) is a genetic disorder that has characteristic metabolic, neurologic, and behavioral features. There are multiple behavioral problems including impulsivity, aggressiveness, and severe recurrent self-injurious behavior (SIB). This last behavior varies considerably across subjects and may encompass self-biting, self-hitting, scratching, head banging, and other injurious actions. Current treatments for SIB involve behavioral extinction, sedatives, physical restraints, and removal of teeth. Because these interventions do not reliably control SIB, better treatments are urgently needed. Animal studies have suggested that D1-dopamine receptor antagonists such as ecopipam may suppress SIB. These observations have led to proposals that such drugs might provide effective treatment for in LND. The current study describes the results of a double-blind, three-period, crossover trial of a single dose of ecopipam in subjects with LND. The study was designed for 20 patients, but it was terminated after recruitment of only 10 patients, because interim analysis revealed unanticipated side effects. These side effects were most likely related to starting with a single large dose without any titration phase. Despite the limited data due to early termination, the drug appeared to reduce SIB in most cases. Subjects who completed the trial were eligible to continue the drug in an open-label extension phase lasting a year, and one patient who elected to continue has maintained a striking reduction in SIB for more than a year with no apparent side effects. These results suggest ecopipam could be a useful treatment for SIB in, but further studies are needed to establish an appropriate dosing regimen.
Asunto(s)
Benzazepinas/administración & dosificación , Antagonistas de Dopamina/administración & dosificación , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Adolescente , Benzazepinas/efectos adversos , Niño , Estudios Cruzados , Antagonistas de Dopamina/efectos adversos , Método Doble Ciego , Humanos , Masculino , Tamaño de la Muestra , Resultado del Tratamiento , Adulto JovenRESUMEN
Lesch-Nyhan disease (LND) is an inherited metabolic disorder characterized by the overproduction of uric acid and distinct behavioral, cognitive, and motor abnormalities. The most challenging clinical problem is self-injurious behavior (SIB), which includes self-biting, self-hitting, self-abrasion, and other features. Currently, these behaviors are managed by behavioral extinction, sedatives, physical restraints, and removal of teeth. More effective treatments are needed. Pre-clinical studies have led to the hypothesis that D1-dopamine receptor antagonists may provide useful treatments for SIB in LND. Ecopipam is one such selective D1-dopamine receptor antagonist. This report summarizes results of a dose-escalation study of the safety and tolerability of ecopipam in 5 subjects with LND. The results suggest that ecopipam is well tolerated, with sedation being the most common dose-limiting event. Several exploratory measures also suggest ecopipam might reduce SIB in this population. These results support the hypothesis that D1-dopamine receptor antagonists may be useful for suppressing SIB in LND, and encourage further studies of efficacy.
Asunto(s)
Benzazepinas/uso terapéutico , Antagonistas de Dopamina/uso terapéutico , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Receptores de Dopamina D1/antagonistas & inhibidores , Adolescente , Adulto , Benzazepinas/administración & dosificación , Benzazepinas/efectos adversos , Niño , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/efectos adversos , Humanos , Síndrome de Lesch-Nyhan/diagnóstico , Síndrome de Lesch-Nyhan/metabolismo , Masculino , Persona de Mediana Edad , Conducta Autodestructiva , Resultado del Tratamiento , Adulto JovenRESUMEN
Current therapies for the Lesch-Nyhan Syndrome (OMIM: 300322) are off-label and experimental, often leading to inconsistent outcomes. We here report the effects of an intrathecal baclofen therapy, carried out at the Scientific Institute Eugenio Medea (Lecco, Italy), on three patients who no longer received benefit from previous therapies. This treatment, as expected, ameliorated the motor symptoms and, unexpectedly, it also improved behavioural components. This result may involve a functional interaction between baclofen and dopamine, complemented by an anxiolytic effect. Our observations provide the rationale for the use of intrathecal baclofen administration in the therapy of the Lesch-Nyhan Syndrome.
Asunto(s)
Baclofeno/administración & dosificación , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Trastornos de la Destreza Motora/tratamiento farmacológico , Conducta Autodestructiva/tratamiento farmacológico , Adulto , Síntomas Conductuales/complicaciones , Síntomas Conductuales/diagnóstico , Síntomas Conductuales/tratamiento farmacológico , Humanos , Síndrome de Lesch-Nyhan/complicaciones , Síndrome de Lesch-Nyhan/diagnóstico , Masculino , Trastornos de la Destreza Motora/complicaciones , Trastornos de la Destreza Motora/diagnóstico , Conducta Autodestructiva/complicaciones , Conducta Autodestructiva/diagnóstico , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Lesch-Nyhan disease (LND) is a rare X-linked recessive neurogenetic disorder caused by deficiency of the purine salvage enzyme hypoxanthine phosphoribosyltransferase (HPRT, EC 2.4.2.8) which is responsible for recycling purine bases into purine nucleotides. Affected individuals have hyperuricemia leading to gout and urolithiasis, accompanied by a characteristic severe neurobehavioural phenotype with compulsive self-mutilation, extrapyramidal motor disturbances and cognitive impairment. AIM: For its theoretical therapeutic potential to replenish the brain purine nucleotide pool, oral supplementation with S-adenosylmethionine (SAMe) was trialed in 5 Malaysian children with LND, comprising 4 related Malay children from 2 families, including an LND girl, and a Chinese Malaysian boy. RESULTS: Dramatic reductions of self-injury and aggressive behaviour, as well as a milder reduction of dystonia, were observed in all 5 patients. Other LND neurological symptoms did not improve during SAMe therapy. DISCUSSION: Molecular mechanisms proposed for LND neuropathology include GTP depletion in the brain leading to impaired dopamine synthesis, dysfunction of G-protein-mediated signal transduction, and defective developmental programming of dopamine neurons. The improvement of our LND patients on SAMe, particularly the hallmark self-injurious behaviour, echoed clinical progress reported with another purine nucleotide depletion disorder, Arts Syndrome, but contrasted lack of benefit with the purine disorder adenylosuccinate lyase deficiency. This first report of a trial of SAMe therapy in LND children showed remarkably encouraging results that warrant larger studies.
Asunto(s)
Síndrome de Lesch-Nyhan/tratamiento farmacológico , S-Adenosilmetionina/uso terapéutico , Adolescente , Agresión/efectos de los fármacos , Niño , Preescolar , Distonía/tratamiento farmacológico , Femenino , Humanos , Lactante , Malasia , Masculino , Linaje , Purinas/metabolismo , Conducta Autodestructiva/tratamiento farmacológicoRESUMEN
A 30-year-old man was referred for investigation and management of hyperuricaemia. History included recurrent nephrolithiasis and chronic gout with poor response to medical management. Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) enzyme activity was investigated and found to be deficient confirming the diagnosis of Lesch-Nyhan disease. Hyperuricaemia was treated with allopurinol. To prevent nephrolithiasis, the patient was instructed to avoid dehydration and aim for a minimum urine output of 2 L/day. Urinary alkalinisation with potassium citrate was started. The patient was referred for genetic counselling. This case discusses the genetics, pathophysiology, clinical manifestations, diagnosis and management of HGPRT deficiency.
Asunto(s)
Hiperuricemia/genética , Hipoxantina Fosforribosiltransferasa/deficiencia , Síndrome de Lesch-Nyhan , Adulto , Alopurinol/uso terapéutico , Diuréticos/uso terapéutico , Asesoramiento Genético , Gota/etiología , Supresores de la Gota/uso terapéutico , Humanos , Hiperuricemia/diagnóstico , Hiperuricemia/tratamiento farmacológico , Hiperuricemia/enzimología , Hipoxantina Fosforribosiltransferasa/genética , Síndrome de Lesch-Nyhan/sangre , Síndrome de Lesch-Nyhan/diagnóstico , Síndrome de Lesch-Nyhan/tratamiento farmacológico , Síndrome de Lesch-Nyhan/enzimología , Masculino , Nefrolitiasis/etiología , Nefrolitiasis/prevención & control , Citrato de Potasio/uso terapéutico , Ácido Úrico/sangreRESUMEN
UNLABELLED: BACKGROUND, RATIONALE, AND METHODS: Lesch-Nyhan disease is a rare, X-linked disorder due to hypoxanthine phosphoribosyltransferase deficiency. To evaluate reported benefit on mood and behavior obtained by the administration of S-adenosyl-L-methionine in this condition, we developed 2 quantitative evaluation tools, and used them to assess the effects of the drug in our population: the weekly questionnaire and the resistance to self-injurious behavior test. We performed an open-label, dose-escalation trial of the drug on 14 patients. RESULTS: Four patients tolerated the drug and reported beneficial effects. The majority experienced worsened behavior. The 2 assessment tools demonstrated effectiveness in quantitatively evaluating the self-injurious behavior.